homocysteines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	homocysteines	go back to main search page
Accession:	CHEBI:24610	browse the term

show annotations for term's descendants Sort by:
Rat (418) Mouse (440) Human (427) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (418)

homocysteic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

[homocysteic acid co-treated with GW 506033X] results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

heat shock transcription factor 1

decreases expression

homocysteic acid results in decreased expression of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

Sp1 transcription factor

increases activity
multiple interactions

homocysteic acid results in increased activity of SP1 protein
mithramycin A inhibits the reaction [homocysteic acid results in increased activity of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

Sp3 transcription factor

multiple interactions
increases activity

mithramycin A inhibits the reaction [homocysteic acid results in increased activity of SP3 protein]

NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342

homocysteine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase medium chain

increases expression

Homocysteine results in increased expression of ACADM mRNA; Homocysteine results in increased expression of ACADM protein

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acetylcholinesterase

increases activity

Homocysteine results in increased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 mRNA; [Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 protein; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 protein]
Homocysteine results in increased expression of ACTA2 mRNA; Homocysteine results in increased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adenosylhomocysteinase

multiple interactions

[Arsenic results in increased expression of and results in increased activity of AHCY protein] which results in increased chemical synthesis of Homocysteine

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

Folic Acid inhibits the reaction [Homocysteine inhibits the reaction [ALB protein binds to Bilirubin]]; Homocysteine inhibits the reaction [ALB protein binds to Bilirubin]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

apolipoprotein A1

decreases expression
multiple interactions

Homocysteine results in decreased expression of APOA1 mRNA; Homocysteine results in decreased expression of APOA1 protein
Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

amyloid beta precursor protein

increases abundance

APP protein results in increased abundance of Homocysteine

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activating transcription factor 1

multiple interactions

Homocysteine promotes the reaction [ATF1 protein binds to CCNA2 promoter]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization
increases expression
affects expression

BAX protein inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]]; BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine affects the localization of BAX protein]]; Cystathionine inhibits the reaction [Homocysteine affects the localization of BAX protein]; Cystathionine inhibits the reaction [Homocysteine results in increased expression of and affects the localization of BAX protein]; Folic Acid affects the reaction [Homocysteine affects the expression of BAX mRNA]; Folic Acid affects the reaction [Homocysteine affects the expression of BAX protein]; Homocysteine results in increased expression of and affects the localization of BAX protein; Zeranol inhibits the reaction [Homocysteine results in increased expression of BAX protein]
Homocysteine results in increased expression of BAX mRNA
Folic Acid inhibits the reaction [Homocysteine results in increased expression of BAX mRNA]
Homocysteine affects the expression of BAX mRNA; Homocysteine affects the expression of BAX protein

PMID:16757814 PMID:29250709 PMID:31721048 PMID:31885769

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

multiple interactions
decreases activity

Folic Acid inhibits the reaction [Homocysteine results in decreased activity of BCHE protein]

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

multiple interactions
affects expression
decreases expression

Folic Acid affects the reaction [Homocysteine affects the expression of BCL2 mRNA]; Folic Acid affects the reaction [Homocysteine affects the expression of BCL2 protein]; Zeranol inhibits the reaction [Homocysteine results in decreased expression of BCL2 protein]
Homocysteine affects the expression of BCL2 mRNA; Homocysteine affects the expression of BCL2 protein
[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA; [Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA]; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein]

PMID:16757814 PMID:22169520 PMID:29250709

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 2

decreases expression
multiple interactions

Homocysteine results in decreased expression of BIRC2 mRNA; Homocysteine results in decreased expression of BIRC2 protein
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases expression
multiple interactions

Homocysteine results in decreased expression of BIRC3 mRNA; Homocysteine results in decreased expression of BIRC3 protein
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

affects binding

Homocysteine analog binds to CACNA2D1 protein

NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969

G

calreticulin

increases expression

Homocysteine results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 1

multiple interactions
increases activity
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; CASP1 protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]; CASP1 protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]; Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; PYCARD protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]; PYCARD protein affects the reaction [Homocysteine results in increased activity of CASP1 protein]
Homocysteine results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions
affects expression
increases expression
affects cleavage
increases activity

BAX protein inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]]; BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased cleavage of CASP3 protein]]; Cystathionine inhibits the reaction [Homocysteine results in increased activity of and results in increased cleavage of CASP3 protein]; Folic Acid affects the reaction [Homocysteine affects the cleavage of CASP3 protein]; Folic Acid affects the reaction [Homocysteine affects the expression of CASP3 mRNA]; Homocysteine results in increased activity of and results in increased cleavage of CASP3 protein; mecobalamin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]
Homocysteine results in increased expression of CASP3 protein
Folic Acid inhibits the reaction [Homocysteine results in increased expression of CASP3 protein]
Atorvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]
Homocysteine results in increased expression of CASP3 mRNA; Homocysteine results in increased expression of CASP3 protein

PMID:16715183 PMID:19343037 PMID:20305681 PMID:21237187 PMID:29250709 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity
multiple interactions

Homocysteine results in increased activity of CASP7 protein
mecobalamin inhibits the reaction [Homocysteine results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions
affects expression

Folic Acid affects the reaction [Homocysteine affects the expression of CASP8 mRNA]; Folic Acid affects the reaction [Homocysteine affects the expression of CASP8 protein]
Homocysteine affects the expression of CASP8 mRNA; Homocysteine affects the expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP9 protein]]; Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases transport
multiple interactions
decreases expression

CAT protein results in decreased transport of Homocysteine
[CAT gene SNP results in increased susceptibility to [Air Pollutants results in increased abundance of Particulate Matter]] which results in increased abundance of Homocysteine
Homocysteine results in decreased expression of CAT protein

PMID:12631446 PMID:22964297 PMID:30477822

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cystathionine beta synthase

affects abundance
multiple interactions

CBS protein affects the abundance of Homocysteine; CBS protein affects the abundance of Homocysteine metabolite
Homocysteine inhibits the reaction [Folic Acid results in increased activity of CBS protein]

PMID:19204075 PMID:23024785 PMID:31721048

NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

[Homocysteine results in increased expression of CCL2 protein] which results in increased phosphorylation of NFKBIA protein; [Homocysteine results in increased expression of CCL2 protein] which results in increased reduction of NFKBIA mRNA; acetovanillone inhibits the reaction [Homocysteine results in increased expression of CCL2 mRNA]; Folic Acid inhibits the reaction [Homocysteine results in increased expression of CCL2 mRNA]
Homocysteine results in increased expression of CCL2 mRNA; Homocysteine results in increased expression of CCL2 protein

PMID:11356643 PMID:16845898

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

[Homocysteine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein
Homocysteine results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 4

decreases expression

Homocysteine results in decreased expression of CCN4 mRNA

NCBI chr 7:98,645,238...98,677,253
Ensembl chr 7:98,645,182...98,677,248

G

cyclin A1

multiple interactions
decreases methylation
decreases expression

DNMT1 protein affects the reaction [Homocysteine results in decreased expression of CCNA1 mRNA]; Homocysteine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Homocysteine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Homocysteine promotes the reaction [H4C16 protein modified form binds to CCNA1 promoter]
Homocysteine results in decreased methylation of CCNA1 promoter

NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157

G

cyclin A2

multiple interactions
increases expression

Dactinomycin inhibits the reaction [Homocysteine results in increased expression of CCNA2 mRNA]; Homocysteine promotes the reaction [ATF1 protein binds to CCNA2 promoter]
Homocysteine results in increased expression of CCNA2 mRNA; Homocysteine results in increased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cadherin 3

multiple interactions
decreases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 mRNA; [Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 protein; acetovanillone inhibits the reaction [Homocysteine results in decreased expression of CDH3 protein]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 protein]; CYBB mutant form inhibits the reaction [Homocysteine results in decreased expression of CDH3 protein]
Homocysteine results in decreased expression of CDH3 mRNA; Homocysteine results in decreased expression of CDH3 protein

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084

G

catechol-O-methyltransferase

multiple interactions

[tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of Homocysteine]

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cytochrome c oxidase subunit 5B

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of COX5B protein

NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052

G

CRK proto-oncogene, adaptor protein

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of CRK protein

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

cytochrome b-245 beta chain

multiple interactions
increases expression
affects localization

CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of CDH3 protein]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of TJP1 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of ACTA2 protein]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 protein]; CYBB mutant form inhibits the reaction [Homocysteine results in decreased expression of CDH3 protein]; CYBB mutant form inhibits the reaction [Homocysteine results in decreased expression of TJP1 protein]; CYBB mutant form inhibits the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB mutant form inhibits the reaction [Homocysteine results in increased expression of S100A4 protein]; CYBB protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]; CYBB protein affects the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS1 mRNA]; CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS2 mRNA]; CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of DES mRNA]; Filipin inhibits the reaction [Homocysteine affects the localization of CYBB protein]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine affects the localization of CYBB protein]
Homocysteine results in increased expression of CYBB mRNA; Homocysteine results in increased expression of CYBB protein

PMID:20036696 PMID:20116427 PMID:21647593

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

dopa decarboxylase

multiple interactions

[Levodopa co-treated with DDC] results in decreased abundance of Homocysteine

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

Glycine inhibits the reaction [Homocysteine results in increased expression of DDIT3 mRNA]; Glycine inhibits the reaction [Homocysteine results in increased expression of DDIT3 protein]
Homocysteine results in increased expression of DDIT3 mRNA; Homocysteine results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

desmin

multiple interactions
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of DES mRNA; acetovanillone inhibits the reaction [Homocysteine results in increased expression of DES mRNA]; acetovanillone inhibits the reaction [Homocysteine results in increased expression of DES protein]; Amitriptyline inhibits the reaction [Homocysteine results in increased expression of DES protein]; CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of DES mRNA]; diphenyleneiodonium inhibits the reaction [Homocysteine results in increased expression of DES mRNA]; diphenyleneiodonium inhibits the reaction [Homocysteine results in increased expression of DES protein]; Filipin inhibits the reaction [Homocysteine results in increased expression of DES mRNA]; Filipin inhibits the reaction [Homocysteine results in increased expression of DES protein]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in increased expression of DES mRNA]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in increased expression of DES protein]
Homocysteine results in increased expression of DES mRNA; Homocysteine results in increased expression of DES protein

PMID:20036696 PMID:20116427 PMID:23024785

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

dynamin 1-like

multiple interactions

Homocysteine results in increased expression of and results in increased phosphorylation of DNM1L protein; xestospongin C inhibits the reaction [Homocysteine results in increased expression of and results in increased phosphorylation of DNM1L protein]

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

DNA methyltransferase 1

decreases activity
multiple interactions

Homocysteine results in decreased activity of DNMT1 protein
DNMT1 protein affects the reaction [Homocysteine results in decreased expression of CCNA1 mRNA]

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

endothelin 1

multiple interactions
affects expression

Zeranol inhibits the reaction [Homocysteine affects the expression of EDN1 protein]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic translation initiation factor 2 alpha kinase 3

decreases phosphorylation

Homocysteine results in decreased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Homocysteine results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

Eph receptor B6

decreases expression

Homocysteine results in decreased expression of EPHB6 mRNA

NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230

G

endoplasmic reticulum to nucleus signaling 1

decreases phosphorylation

Homocysteine results in decreased phosphorylation of ERN1 protein

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

endoplasmic reticulum oxidoreductase 1 alpha

decreases expression

Homocysteine results in decreased expression of ERO1A protein

NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478

G

exosome component 4

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of EXOSC4 protein

NCBI chr 7:108,047,831...108,050,573
Ensembl chr 7:108,047,831...108,050,573

G

GATA binding protein 4

decreases expression
multiple interactions

Homocysteine results in decreased expression of GATA4 mRNA; Homocysteine results in decreased expression of GATA4 protein
Particulate Matter promotes the reaction [Homocysteine results in decreased expression of GATA4 protein]

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

growth hormone 1

decreases abundance

GH1 protein results in decreased abundance of Homocysteine

PMID:17311540 PMID:17324600

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

glutamic--pyruvic transaminase

increases activity
multiple interactions

Homocysteine results in increased activity of GPT protein
Folic Acid inhibits the reaction [Homocysteine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

decreases activity
decreases expression

Homocysteine results in decreased activity of GPX1 protein
Homocysteine results in decreased expression of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor NMDA type subunit 1

increases expression

Homocysteine analog results in increased expression of GRIN1 protein

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutathione-disulfide reductase

decreases expression

Homocysteine results in decreased expression of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase, mu 5

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of GSTM3 protein

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase pi 1

multiple interactions

[GSTP1 gene SNP results in increased susceptibility to [Air Pollutants results in increased abundance of Particulate Matter]] which results in increased abundance of Homocysteine

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

H3.4 histone, cluster member

multiple interactions

Homocysteine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]

NCBI chr10:43,740,702...43,741,262

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

Glycine inhibits the reaction [Homocysteine results in increased expression of HSPA5 mRNA]
Homocysteine results in increased expression of HSPA5 mRNA; Homocysteine results in increased expression of HSPA5 protein

PMID:19960509 PMID:27064126

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 9

multiple interactions

Homocysteine promotes the reaction [HSPA9 protein binds to ITPR1 protein]; Homocysteine promotes the reaction [HSPA9 protein binds to VDAC1 protein]

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

insulin 1

multiple interactions

[Alloxan co-treated with Homocysteine] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Homocysteine inhibits the reaction [Glucose results in increased secretion of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

ISL LIM homeobox 1

affects expression
multiple interactions

Homocysteine affects the expression of ISL1 mRNA
Folic Acid inhibits the reaction [Homocysteine affects the expression of ISL1 mRNA]; Inositol promotes the reaction [Folic Acid inhibits the reaction [Homocysteine affects the expression of ISL1 mRNA]]

NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584

G

inositol 1,4,5-trisphosphate receptor, type 1

increases expression
multiple interactions

Homocysteine results in increased expression of ITPR1 protein
Homocysteine promotes the reaction [HSPA9 protein binds to ITPR1 protein]

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

Kelch-like ECH-associated protein 1

increases expression

Homocysteine results in increased expression of KEAP1 protein

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; [1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester co-treated with Genistein] inhibits the reaction [Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]]; Acetylcysteine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Folic Acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; fulvic acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Genistein inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Genistein inhibits the reaction [Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]]; Go 6976 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Phorbol 12,13-Dibutyrate promotes the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]
6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; alpha-methyl-4-carboxyphenylglycine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Cystine affects the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Dizocilpine Maleate inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]

PMID:16251475 PMID:19850060 PMID:25888188

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; Atorvastatin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; diphenyleneiodonium inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; NOX4 mutant form inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]

PMID:19767766 PMID:20018284 PMID:20305681

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; [1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester co-treated with Genistein] inhibits the reaction [Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]]; Acetylcysteine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Folic Acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; fulvic acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Genistein inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Genistein inhibits the reaction [Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]]; Go 6976 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Phorbol 12,13-Dibutyrate promotes the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Thapsigargin promotes the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]
6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; alpha-methyl-4-carboxyphenylglycine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Cystine affects the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Dizocilpine Maleate inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]

PMID:16251475 PMID:19850060 PMID:25888188

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

Homocysteine results in increased phosphorylation of MAPK8 protein
fulvic acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases phosphorylation
multiple interactions

Homocysteine results in increased phosphorylation of MAPK9 protein
fulvic acid inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

mitochondrial calcium uniporter

increases expression

Homocysteine results in increased expression of MCU protein

NCBI chr20:27,417,529...27,580,110
Ensembl chr20:27,417,526...27,580,110

G

methyl CpG binding protein 2

multiple interactions

Homocysteine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]

NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689

G

mitofusin 2

decreases expression

Homocysteine results in decreased expression of MFN2 protein

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

matrix metallopeptidase 1

multiple interactions

Dizocilpine Maleate inhibits the reaction [Homocysteine analog results in decreased expression of and results in decreased activity of MMP1 protein]; Homocysteine analog results in decreased expression of and results in decreased activity of MMP1 protein

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 9

multiple interactions
decreases expression
increases expression
increases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased activity of MMP9 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased expression of MMP9 protein]; Acetylcysteine inhibits the reaction [Homocysteine results in increased activity of MMP9 protein]; Acetylcysteine inhibits the reaction [Homocysteine results in increased expression of MMP9 protein]; Staurosporine inhibits the reaction [Homocysteine results in increased activity of MMP9 protein]; Staurosporine inhibits the reaction [Homocysteine results in increased expression of MMP9 protein]
Dizocilpine Maleate inhibits the reaction [Homocysteine analog results in decreased expression of MMP9 protein]
Homocysteine results in increased activity of and results in increased expression of MMP9 protein

PMID:16251475 PMID:20406136 PMID:22326992

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

metallothionein 1

multiple interactions
decreases expression

[Folic Acid co-treated with Zinc] inhibits the reaction [Homocysteine results in decreased expression of MT1A mRNA]; Folic Acid inhibits the reaction [Homocysteine results in decreased expression of MT1A mRNA]; Zinc inhibits the reaction [Homocysteine results in decreased expression of MT1A mRNA]

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

methylenetetrahydrofolate reductase

increases expression
multiple interactions
affects abundance
decreases methylation
increases abundance
affects metabolic processing

Homocysteine results in increased expression of MTHFR protein
[MTHFR gene mutant form co-treated with Methotrexate] results in increased abundance of Homocysteine
MTHFR protein affects the abundance of Homocysteine metabolite
Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein]
MTHFR protein SNP results in decreased methylation of Homocysteine
MTHFR gene polymorphism results in increased abundance of Homocysteine; MTHFR protein mutant form results in increased abundance of Homocysteine
MTHFR protein affects the metabolism of Homocysteine

PMID:7647779 PMID:17387702 PMID:18540024 PMID:19204075 PMID:19593106 More...

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

5-methyltetrahydrofolate-homocysteine methyltransferase

affects metabolic processing
multiple interactions
affects binding

MTR gene polymorphism affects the metabolism of Homocysteine
Homocysteine inhibits the reaction [Folic Acid results in increased activity of MTR protein]
Homocysteine binds to MTR protein

PMID:17477549 PMID:20532609 PMID:31721048

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

5-methyltetrahydrofolate-homocysteine methyltransferase reductase

affects abundance

MTRR protein affects the abundance of Homocysteine

NCBI chr 1:34,866,991...34,899,425
Ensembl chr 1:34,867,089...34,899,425

G

neutrophil cytosolic factor 1

affects localization
increases phosphorylation
multiple interactions

Homocysteine affects the localization of NCF1 protein
Homocysteine results in increased phosphorylation of NCF1 protein
Filipin inhibits the reaction [Homocysteine affects the localization of NCF1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine affects the localization of NCF1 protein]
Folic Acid inhibits the reaction [Homocysteine results in increased phosphorylation of NCF1 protein]; Homocysteine promotes the reaction [NCF1 protein results in increased abundance of Reactive Oxygen Species]; Homocysteine results in increased localization of and results in increased activity of NCF1 protein

PMID:16845898 PMID:17586618 PMID:20036696

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

NFE2 like bZIP transcription factor 2

affects localization
multiple interactions
increases expression

Homocysteine affects the localization of NFE2L2 protein modified form
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Homocysteine results in decreased expression of NFE2L2 protein]; Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein; L 709049 inhibits the reaction [Homocysteine results in decreased expression of NFE2L2 protein]; N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal inhibits the reaction [Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein]; Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein
Homocysteine results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions
increases degradation

[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA; [Homocysteine results in increased expression of CCL2 protein] which results in increased phosphorylation of NFKBIA protein; [Homocysteine results in increased expression of CCL2 protein] which results in increased reduction of NFKBIA mRNA; acetovanillone inhibits the reaction [Homocysteine results in increased phosphorylation of and results in increased activity of NFKBIA protein]; Folic Acid inhibits the reaction [Homocysteine results in increased phosphorylation of and results in increased activity of NFKBIA protein]; Homocysteine results in increased phosphorylation of and results in increased activity of NFKBIA protein
Homocysteine results in increased degradation of NFKBIA protein

PMID:11356643 PMID:16845898 PMID:17586618 PMID:24224954

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor beta

increases degradation

Homocysteine results in increased degradation of NFKBIB protein

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

NK2 homeobox 5

multiple interactions
decreases expression

Particulate Matter promotes the reaction [Homocysteine results in decreased expression of NKX2-5 protein]
Homocysteine results in decreased expression of NKX2-5 mRNA; Homocysteine results in decreased expression of NKX2-5 protein

NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934

G

NLR family, CARD domain containing 3

multiple interactions
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; CASP1 protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]; Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; PYCARD protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]
Homocysteine results in increased expression of NLRC3 mRNA

NCBI chr10:11,551,378...11,585,027
Ensembl chr10:11,551,356...11,584,398

G

nitric oxide synthase 2

increases methylation
increases expression
multiple interactions

Homocysteine results in increased methylation of NOS2 promoter
Homocysteine results in increased expression of NOS2 mRNA
Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]
[Homocysteine results in increased methylation of NOS2 promoter] which results in decreased expression of NOS2 mRNA; Clofibrate inhibits the reaction [Homocysteine results in increased methylation of NOS2 promoter]; pioglitazone inhibits the reaction [Homocysteine results in increased methylation of NOS2 promoter]

PMID:17492134 PMID:18540024

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
decreases expression
decreases phosphorylation

Folic Acid inhibits the reaction [Homocysteine results in decreased expression of and results in decreased activity of NOS3 protein]; Homocysteine results in decreased expression of and results in decreased activity of NOS3 protein; Zeranol inhibits the reaction [Homocysteine results in decreased expression of NOS3 protein]
Homocysteine results in decreased expression of NOS3 mRNA; Homocysteine results in decreased expression of NOS3 protein
Homocysteine results in decreased phosphorylation of NOS3 protein
Atorvastatin inhibits the reaction [Homocysteine results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of NOS3 protein]

PMID:16757814 PMID:17357445 PMID:20305681

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NADPH oxidase 4

multiple interactions
increases response to substance
increases expression

Atorvastatin inhibits the reaction [Homocysteine results in increased expression of NOX4 mRNA]; NOX4 mutant form inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]
NOX4 results in increased susceptibility to Homocysteine

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

NPHS2 stomatin family member, podocin

multiple interactions
decreases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS2 mRNA; acetovanillone inhibits the reaction [Homocysteine results in decreased expression of NPHS2 mRNA]; acetovanillone inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein]; Amitriptyline inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein]; CYBB protein mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of NPHS2 mRNA]; diphenyleneiodonium inhibits the reaction [Homocysteine results in decreased expression of NPHS2 mRNA]; diphenyleneiodonium inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein]; Filipin inhibits the reaction [Homocysteine results in decreased expression of NPHS2 mRNA]; Filipin inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in decreased expression of NPHS2 mRNA]; methyl-beta-cyclodextrin inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein]
Homocysteine results in decreased expression of NPHS2 mRNA; Homocysteine results in decreased expression of NPHS2 protein

PMID:20036696 PMID:20116427 PMID:23024785

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

5' nucleotidase, ecto

affects activity

Homocysteine affects the activity of NT5E protein

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

phosphofurin acidic cluster sorting protein 2

increases expression

Homocysteine results in increased expression of PACS2 protein

NCBI chr 6:132,096,992...132,156,702
Ensembl chr 6:132,096,901...132,154,583

G

paraoxonase 1

multiple interactions

[Methionine results in increased abundance of Homocysteine] which results in decreased activity of PON1 protein; [resveratrol results in increased abundance of Homocysteine] which results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxiredoxin 6

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of PRDX6 protein

NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; fulvic acid inhibits the reaction [Homocysteine promotes the reaction [RELA protein binds to PTGS2 promoter]]; fulvic acid inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; Homocysteine promotes the reaction [RELA protein binds to PTGS2 promoter]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; SN50 peptide inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PYD and CARD domain containing

multiple interactions
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; CASP1 protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]; Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]; PYCARD protein affects the reaction [Homocysteine promotes the reaction [NLRC3 protein binds to PYCARD protein binds to CASP1 protein]]; PYCARD protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]; PYCARD protein affects the reaction [Homocysteine results in increased activity of CASP1 protein]
Homocysteine results in increased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RAB1B, member RAS oncogene family

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of RAB1B protein

NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868
Ensembl chr X:202,405,759...202,413,868

G

RAB9A, member RAS oncogene family

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of RAB9A protein

NCBI chr X:27,955,552...28,009,870
Ensembl chr X:27,952,204...28,001,622

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression
increases localization
increases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Homocysteine results in increased activity of RELA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; fulvic acid inhibits the reaction [Homocysteine promotes the reaction [RELA protein binds to PTGS2 promoter]]; Homocysteine promotes the reaction [RELA protein binds to PTGS2 promoter]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased activity of RELA protein]
Homocysteine results in increased expression of RELA protein
Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]
Homocysteine results in increased localization of RELA protein

PMID:17586618 PMID:18540024 PMID:24224954 PMID:25888188

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

S100 calcium-binding protein A4

multiple interactions
increases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 mRNA; [Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 protein; acetovanillone inhibits the reaction [Homocysteine results in increased expression of S100A4 protein]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 mRNA]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in increased expression of S100A4 protein]; CYBB mutant form inhibits the reaction [Homocysteine results in increased expression of S100A4 protein]
Homocysteine results in increased expression of S100A4 mRNA; Homocysteine results in increased expression of S100A4 protein

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

solute carrier family 46 member 1

affects abundance

SLC46A1 protein affects the abundance of Homocysteine metabolite

NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848

G

superoxide dismutase 1

increases expression

Homocysteine results in increased expression of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

[SOD2 gene SNP results in increased susceptibility to [Air Pollutants results in increased abundance of Particulate Matter]] which results in increased abundance of Homocysteine

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

signal sequence receptor subunit 4

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of SSR4 protein

NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

Dizocilpine Maleate inhibits the reaction [Homocysteine analog results in increased expression of TIMP1 mRNA]; Dizocilpine Maleate inhibits the reaction [Homocysteine analog results in increased expression of TIMP1 protein]
Homocysteine analog results in increased expression of TIMP1 mRNA; Homocysteine analog results in increased expression of TIMP1 protein

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tight junction protein 1

multiple interactions
decreases expression

[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of TJP1 mRNA; acetovanillone inhibits the reaction [Homocysteine results in decreased expression of TJP1 protein]; CYBB mutant form inhibits the reaction [[Folic Acid deficiency results in increased abundance of Homocysteine] which results in decreased expression of TJP1 mRNA]; CYBB mutant form inhibits the reaction [Homocysteine results in decreased expression of TJP1 protein]
Homocysteine results in decreased expression of TJP1 mRNA; Homocysteine results in decreased expression of TJP1 protein

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

multiple interactions
increases expression

[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein
Homocysteine results in increased expression of TNF protein

PMID:24224954 PMID:27203204

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

tumor protein p53

increases phosphorylation
affects expression
multiple interactions

Homocysteine results in increased phosphorylation of TP53 protein
Homocysteine affects the expression of TP53 mRNA; Homocysteine affects the expression of TP53 protein
Folic Acid affects the reaction [Homocysteine affects the expression of TP53 mRNA]; Folic Acid affects the reaction [Homocysteine affects the expression of TP53 protein]

PMID:13679428 PMID:29250709

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

VHL binding protein 1

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of VBP1 protein

G

vascular cell adhesion molecule 1

multiple interactions
increases expression

3,4-dihydroxyphenylethanol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]; resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]
Homocysteine results in increased expression of VCAM1 mRNA; Homocysteine results in increased expression of VCAM1 protein

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

voltage-dependent anion channel 1

increases expression
multiple interactions

Homocysteine results in increased expression of VDAC1 protein
Homocysteine promotes the reaction [HSPA9 protein binds to VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vascular endothelial growth factor A

multiple interactions
increases expression
decreases expression
decreases secretion

Amitriptyline inhibits the reaction [Homocysteine results in decreased secretion of VEGFA protein]; CASP1 protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]; CYBB protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]; diphenyleneiodonium inhibits the reaction [Homocysteine results in decreased secretion of VEGFA protein]; Homocysteine results in decreased expression of and results in decreased secretion of VEGFA protein; PYCARD protein affects the reaction [Homocysteine results in decreased secretion of VEGFA protein]
Homocysteine results in increased expression of VEGFA protein
Homocysteine results in decreased expression of VEGFA mRNA

PMID:17485853 PMID:20116427 PMID:22647887 PMID:23024785

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

increases expression

Homocysteine results in increased expression of VIM protein

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

VPS29 retromer complex component

multiple interactions

[Methionine deficiency co-treated with Homocysteine] affects the expression of VPS29 protein

NCBI chr12:34,208,911...34,217,977
Ensembl chr12:34,207,263...34,217,964

G

Wnt family member 5A

decreases expression

Homocysteine results in decreased expression of WNT5A mRNA

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

X-box binding protein 1

multiple interactions
decreases expression
increases expression
increases splicing

Glycine affects the reaction [Homocysteine results in increased splicing of XBP1 mRNA]
Homocysteine results in decreased expression of XBP1 protein
Homocysteine results in increased expression of XBP1 mRNA alternative form

PMID:19960509 PMID:22964297 PMID:27064126

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

L-cystathionine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

BAX protein inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]]; BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine affects the localization of BAX protein]]; Cystathionine inhibits the reaction [Homocysteine affects the localization of BAX protein]; Cystathionine inhibits the reaction [Homocysteine results in increased expression of and affects the localization of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions

BAX protein inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]]; BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased cleavage of CASP3 protein]]; Cystathionine inhibits the reaction [Homocysteine results in increased activity of and results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

BTSA1 compound inhibits the reaction [Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP9 protein]]; Cystathionine inhibits the reaction [Homocysteine results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

insulin 2

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cystathionine analog

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

kynurenine aminotransferase 1

increases amination

KYAT1 protein results in increased amination of Cystathionine

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

matrix metallopeptidase 1

multiple interactions

Cystathionine inhibits the reaction [Formaldehyde results in increased expression of MMP1 protein]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

S-adenosyl-L-homocysteine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosylhomocysteinase

increases hydrolysis

AHCY results in increased hydrolysis of S-Adenosylhomocysteine

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

aryl hydrocarbon receptor

increases abundance
multiple interactions

AHR protein results in increased abundance of S-Adenosylhomocysteine
PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

5'-aminolevulinate synthase 2

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

amyloid beta precursor protein

increases expression
decreases methylation
multiple interactions

S-Adenosylhomocysteine results in increased expression of APP protein
S-Adenosylhomocysteine results in decreased methylation of APP promoter
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]; S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein

PMID:19635394 PMID:22064374

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

ATPase copper transporting beta

increases abundance

ATP7B protein mutant form results in increased abundance of S-Adenosylhomocysteine

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

beta-secretase 1

increases expression

S-Adenosylhomocysteine results in increased expression of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

coactivator-associated arginine methyltransferase 1

decreases activity

S-Adenosylhomocysteine results in decreased activity of CARM1 protein

NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689

G

collagen type I alpha 1 chain

decreases expression

S-Adenosylhomocysteine results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

decreases expression

S-Adenosylhomocysteine results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

catechol-O-methyltransferase

decreases activity

S-Adenosylhomocysteine results in decreased activity of COMT protein

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

DNA methyltransferase 1

decreases activity
multiple interactions

S-Adenosylhomocysteine results in decreased activity of DNMT1 protein
S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]

PMID:16037419 PMID:22064374

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

fibroblast growth factor 19

decreases abundance

FGF19 protein results in decreased abundance of S-Adenosylhomocysteine

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

hemoglobin subunit beta

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hydroxymethylbilane synthase

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]

NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957

G

matrix metallopeptidase 2

increases expression
multiple interactions

S-Adenosylhomocysteine results in increased expression of MMP2 mRNA; S-Adenosylhomocysteine results in increased expression of MMP2 protein
S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter]
U 0126 inhibits the reaction [S-Adenosylhomocysteine results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NFKB inhibitor alpha

decreases expression

S-Adenosylhomocysteine results in decreased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of S-Adenosylhomocysteine

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

8-oxoguanine DNA glycosylase

multiple interactions
decreases methylation
decreases expression

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]; S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]
S-Adenosylhomocysteine results in decreased expression of OGG1 mRNA; S-Adenosylhomocysteine results in decreased expression of OGG1 protein

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

PPARG coactivator 1 alpha

increases expression

S-Adenosylhomocysteine results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein arginine methyltransferase 1

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT1 protein

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

protein arginine methyltransferase 5

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT5 protein

NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296

G

protein arginine methyltransferase 6

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT6 protein

NCBI chr 2:197,927,750...197,932,760
Ensembl chr 2:197,927,220...197,933,648

G

protein arginine methyltransferase 7

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT7 protein

NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577

G

presenilin 1

multiple interactions
decreases methylation
increases expression

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]
S-Adenosylhomocysteine results in increased expression of PSEN1 protein

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

solute carrier family 19 member 1

affects abundance

SLC19A1 protein affects the abundance of S-Adenosylhomocysteine

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

Sp1 transcription factor

multiple interactions

S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

TIMP metallopeptidase inhibitor 2

decreases expression

S-Adenosylhomocysteine results in decreased expression of TIMP2 protein

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

S-butyl-DL-homocysteine (S,R)-sulfoximine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

affects localization
multiple interactions

Buthionine Sulfoximine affects the localization of ABCC1 protein mutant form
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to monomethylarsonous acid analog]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to methylarsine analog]

PMID:15180633 PMID:15473893 PMID:15581632 PMID:21918036

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

apoptotic chromatin condensation inducer 1

increases expression

Buthionine Sulfoximine results in increased expression of ACIN1 protein

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

aconitase 2

decreases activity

Buthionine Sulfoximine results in decreased activity of ACO2 protein

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

actin, beta

decreases expression

Buthionine Sulfoximine results in decreased expression of ACTB mRNA

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

adducin 3

increases expression

Buthionine Sulfoximine results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

Buthionine Sulfoximine promotes the reaction [Ethanol results in increased expression of ADH1 mRNA]

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

aminoacyl tRNA synthetase complex-interacting multifunctional protein 1

increases expression

Buthionine Sulfoximine results in increased expression of AIMP1 mRNA

NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728

G

AKT serine/threonine kinase 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased phosphorylation of AKT1 protein]
Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of AKT1 protein]

PMID:24449419 PMID:36343453

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aminolevulinate dehydratase

decreases activity

Buthionine Sulfoximine results in decreased activity of ALAD protein

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

5'-aminolevulinate synthase 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [1,2,4-trichlorobenzene results in increased activity of ALAS1 protein]

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

albumin

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldolase, fructose-bisphosphate A

increases expression

Buthionine Sulfoximine results in increased expression of ALDOA mRNA; Buthionine Sulfoximine results in increased expression of ALDOA protein

PMID:11841787 PMID:23736079

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

alpha-1-microglobulin/bikunin precursor

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of AMBP mRNA

NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression

Buthionine Sulfoximine results in increased expression of APEX1 protein

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

apolipoprotein H

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of APOH mRNA

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

amyloid beta precursor protein

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

Buthionine Sulfoximine results in decreased expression of ARNT protein

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

decreases expression

Buthionine Sulfoximine results in decreased expression of ATP2A2 protein

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATP synthase F1 subunit beta

increases expression

Buthionine Sulfoximine results in increased expression of ATP5F1B mRNA

NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273

G

ataxin 1

affects localization
multiple interactions

Buthionine Sulfoximine affects the localization of ATXN1 protein mutant form
Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form]

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

Axl receptor tyrosine kinase

increases expression

Buthionine Sulfoximine results in increased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

antizyme inhibitor 1

decreases expression

Buthionine Sulfoximine results in decreased expression of AZIN1 mRNA

NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of BAX protein
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein]

PMID:11341981 PMID:18552690

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of BCL2 mRNA; Buthionine Sulfoximine results in decreased expression of BCL2 protein
Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein]
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein]
Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA]

PMID:11341981 PMID:17989939 PMID:18552690 PMID:25410294

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 1

decreases expression

Buthionine Sulfoximine results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

calreticulin

increases expression

Buthionine Sulfoximine results in increased expression of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

multiple interactions
increases expression
increases activity

4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in increased expression of CASP3 mRNA]
[O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate co-treated with Buthionine Sulfoximine] results in increased cleavage of CASP3 protein; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of and results in increased cleavage of CASP3 protein]; Buthionine Sulfoximine results in increased expression of and results in increased cleavage of CASP3 protein
[Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [Vitamin K 3 results in increased activity of CASP3 protein]

PMID:10673743 PMID:15276415 PMID:15963344 PMID:16310883 PMID:17200146 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP4 protein]

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

caspase 7

multiple interactions

Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions

[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Buthionine Sulfoximine results in decreased activity of CAT protein
Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in decreased abundance of Glutathione]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]

PMID:21620807 PMID:21772021 PMID:26187465

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 11

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL11 mRNA

PMID:22407903 PMID:27421576

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]

PMID:22407903 PMID:26177832 PMID:31294483 PMID:35123994

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of CCND1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD163 molecule

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA]

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD36 molecule

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of CD36 protein
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CD36 mRNA promotes the reaction [Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; CD36 mRNA promotes the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]

PMID:26187465 PMID:27358406 PMID:28263783

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD59b molecule

increases mutagenesis

Buthionine Sulfoximine results in increased mutagenesis of CD59 gene

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

Cd68 molecule

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CD86 molecule

increases expression

Buthionine Sulfoximine results in increased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1A protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1B protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

checkpoint kinase 2

multiple interactions

Buthionine Sulfoximine promotes the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form]

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

calcium homeostasis endoplasmic reticulum protein

increases expression

Buthionine Sulfoximine results in increased expression of CHERP protein

NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507

G

collagen type I alpha 1 chain

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type V alpha 3 chain

decreases expression

Buthionine Sulfoximine results in decreased expression of COL5A3 mRNA

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

cytochrome c oxidase subunit 4i1

increases expression

Buthionine Sulfoximine results in increased expression of COX4I1 mRNA

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

chromosome segregation 1 like

increases expression

Buthionine Sulfoximine results in increased expression of CSE1L protein

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

colony stimulating factor 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CSF1 mRNA]

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

C-X-C motif chemokine ligand 1

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA]

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 12

decreases expression
increases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of CXCL12 mRNA
Buthionine Sulfoximine results in increased expression of CXCL12 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CXCL12 mRNA]

PMID:15878706 PMID:35123994

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 2

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA]

PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 PMID:31294483

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

[Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL1 mRNA; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of CXCL1 protein]

PMID:26149495 PMID:31294483

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 4

decreases expression

Buthionine Sulfoximine results in decreased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
increases activity

Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine results in decreased activity of CYP1A1 protein
Buthionine Sulfoximine results in increased activity of CYP1A1 protein
[Buthionine Sulfoximine co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; [Buthionine Sulfoximine co-treated with Cadmium Chloride] results in increased expression of CYP1A1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of CYP1A1 mRNA; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine promotes the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

PMID:9756946 PMID:16274885 PMID:16906435 PMID:18078826 PMID:19033395 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases response to substance
multiple interactions

CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine; CYP2E1 results in increased susceptibility to Buthionine Sulfoximine
Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]; Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin promotes the reaction [CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Buthionine Sulfoximine]

PMID:10498651 PMID:12086689 PMID:12566070 PMID:22486562

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione; Buthionine Sulfoximine promotes the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; neferine promotes the reaction [[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DAB adaptor protein 1

decreases expression

Buthionine Sulfoximine results in decreased expression of DAB1 mRNA

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

aspartyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of DARS1 protein

NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116

G

DNA-damage inducible transcript 3

multiple interactions

Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of DDIT3 protein]

PMID:17171638 PMID:25341683

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

diacylglycerol O-acyltransferase 2

decreases expression

Buthionine Sulfoximine results in decreased expression of DGAT2 mRNA

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

iodothyronine deiodinase 2

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

increases activity

Buthionine Sulfoximine results in increased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dihydrolipoamide dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of DLD protein

NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795

G

enoyl-CoA hydratase 1

increases expression

Buthionine Sulfoximine results in increased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

eukaryotic translation elongation factor 1 alpha 1

increases expression

Buthionine Sulfoximine results in increased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

eukaryotic translation elongation factor 1 beta 2

increases expression

Buthionine Sulfoximine results in increased expression of EEF1B2 mRNA

NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737

G

epidermal growth factor

multiple interactions

Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 1A

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF1A mRNA

NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2B subunit delta

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF2B4 mRNA

NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829

G

eukaryotic translation initiation factor 3, subunit G

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF3G mRNA

NCBI chr 8:19,429,728...19,433,760
Ensembl chr 8:19,429,643...19,433,808

G

extended synaptotagmin 1

decreases expression

Buthionine Sulfoximine results in decreased expression of ESYT1 mRNA

NCBI chr 7:928,848...946,199
Ensembl chr 7:928,848...946,199

G

eukaryotic translation termination factor 1

increases expression

Buthionine Sulfoximine results in increased expression of ETF1 mRNA

NCBI chr18:26,502,413...26,530,753
Ensembl chr18:26,504,080...26,530,810

G

enhancer of zeste 1 polycomb repressive complex 2 subunit

decreases expression

Buthionine Sulfoximine results in decreased expression of EZH1 mRNA

NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921

G

Fas cell surface death receptor

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Copper deficiency results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FKBP prolyl isomerase 5

increases expression

Buthionine Sulfoximine results in increased expression of FKBP5 protein

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

Fms related receptor tyrosine kinase 1

increases expression

Buthionine Sulfoximine results in increased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

flavin containing dimethylaniline monoxygenase 3

multiple interactions

Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea]

NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028

G

fibronectin 1

multiple interactions

[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of FOS mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA]

PMID:7743507 PMID:15520183 PMID:18449455 PMID:21825963

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOSL1 mRNA]
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of FOSL1 mRNA]

PMID:15520183 PMID:19010381

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box P3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of FOXP3 mRNA

PMID:23986454 PMID:26177832

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

ferritin heavy chain 1

multiple interactions
increases expression

Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA]
Buthionine Sulfoximine results in increased expression of FTH1 mRNA

PMID:15878706 PMID:16631525

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glucose-6-phosphate dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions
increases expression

[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone binds to GAPDH protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone results in decreased activity of GAPDH protein]
Buthionine Sulfoximine results in increased expression of GAPDH mRNA

PMID:15878706 PMID:21827172

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

GATA binding protein 3

multiple interactions
decreases expression

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GATA3 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA
Buthionine Sulfoximine results in decreased expression of GATA3 mRNA

PMID:22407903 PMID:23986454 PMID:26177832 PMID:27421576

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

GC, vitamin D binding protein

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of GC mRNA

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glutamate-cysteine ligase, catalytic subunit

increases activity
decreases expression
increases expression
multiple interactions
decreases activity

Buthionine Sulfoximine results in increased activity of GCLC protein
Buthionine Sulfoximine results in decreased expression of GCLC protein
Buthionine Sulfoximine results in increased expression of GCLC mRNA
[Buthionine Sulfoximine results in decreased activity of GCLC protein] inhibits the reaction [indenoindole results in increased abundance of Glutathione]; [Buthionine Sulfoximine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione; [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in decreased susceptibility to naphthalene]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [naphthalene results in increased activity of GCLC protein]; Buthionine Sulfoximine promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of GCLC mRNA]
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; Buthionine Sulfoximine inhibits the reaction [GCLC results in decreased susceptibility to Cadmium Chloride]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in decreased expression of GCLC protein]
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in increased chemical synthesis of gamma-glutamylcysteine]; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GCLC mRNA]

PMID:7955076 PMID:10900227 PMID:10915739 PMID:10978506 PMID:11019651 More...

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of GCLM mRNA
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione]
[Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]

PMID:10978506 PMID:17724089 PMID:19010381 PMID:22864849

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of GDF15 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GDF15 mRNA]

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDP dissociation inhibitor 2

decreases expression

Buthionine Sulfoximine results in decreased expression of GDI2 mRNA

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glial fibrillary acidic protein

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutaredoxin

multiple interactions

Buthionine Sulfoximine inhibits the reaction [arsenite results in increased expression of GLRX protein]

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glia maturation factor, beta

increases response to substance

GMFB protein results in increased susceptibility to Buthionine Sulfoximine

NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331

G

glucose-6-phosphate isomerase

increases expression

Buthionine Sulfoximine results in increased expression of GPI1 mRNA

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

glutamic--pyruvic transaminase

multiple interactions

[allyl sulfide co-treated with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate] inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein; [Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased expression of and results in increased activity of GPT protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]; Tranylcypromine inhibits the reaction [[Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]

PMID:15950962 PMID:26177832 PMID:27421576 PMID:29679711 PMID:30853469 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

affects activity
multiple interactions

Buthionine Sulfoximine affects the activity of GPX1 protein
Buthionine Sulfoximine promotes the reaction [Microcystins analog results in increased expression of GPX1 mRNA]
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of GPX1 mRNA]

PMID:15707499 PMID:24964298 PMID:25341683

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression

Buthionine Sulfoximine results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 3

increases expression

Buthionine Sulfoximine results in increased expression of GPX3 mRNA

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutathione peroxidase 4

multiple interactions

Buthionine Sulfoximine promotes the reaction [Acrolein results in decreased expression of GPX4 mRNA]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth factor receptor bound protein 2

decreases expression

Buthionine Sulfoximine results in decreased expression of GRB2 mRNA

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

glycogen synthase kinase 3 beta

decreases phosphorylation

Buthionine Sulfoximine results in decreased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

gelsolin

increases expression

Buthionine Sulfoximine results in increased expression of GSN mRNA

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

G

glutathione-disulfide reductase

multiple interactions

Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]
Buthionine Sulfoximine inhibits the reaction [arsenite results in increased activity of GSR protein]
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in decreased expression of GSR mRNA]; Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased expression of GSR mRNA]

PMID:12967637 PMID:16288907 PMID:17119269 PMID:21772021 PMID:24634002 More...

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

decreases activity
increases expression

Buthionine Sulfoximine results in decreased activity of GSS protein
Buthionine Sulfoximine results in increased expression of GSS mRNA

PMID:10904027 PMID:10978506

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase alpha 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of GSTA1 mRNA]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 1

increases expression

Buthionine Sulfoximine results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

Buthionine Sulfoximine results in increased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase pi 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [GSTP1 results in decreased susceptibility to Benzo(a)pyrene]
Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GSTP1 mRNA]

PMID:19330882 PMID:24964298

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

hydroxyacyl-CoA dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

HBS1-like translational GTPase

decreases expression

Buthionine Sulfoximine results in decreased expression of HBS1L mRNA

NCBI chr 1:16,092,529...16,170,082
Ensembl chr 1:16,092,547...16,170,074

G

heparin binding growth factor

increases expression

Buthionine Sulfoximine results in increased expression of HDGF mRNA

NCBI chr 2:173,370,147...173,379,756
Ensembl chr 2:173,370,465...173,379,747

G

hepatocyte growth factor

increases expression

Buthionine Sulfoximine results in increased expression of HGF protein

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
increases activity

Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HIF1A protein]
Buthionine Sulfoximine results in increased activity of HIF1A protein

PMID:11641398 PMID:11841787 PMID:17658243

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein]

PMID:23986454 PMID:26177832

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group box 2

increases expression

Buthionine Sulfoximine results in increased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140

G

heme oxygenase 1

multiple interactions
increases expression

1-aminobenzotriazole inhibits the reaction [[Acetaminophen co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Butylated Hydroxyanisole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Diclofenac co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Butylated Hydroxyanisole results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]
Buthionine Sulfoximine results in increased expression of HMOX1 protein
Buthionine Sulfoximine results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine results in increased expression of HMOX1 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[sodium arsenite co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 protein]

PMID:7626009 PMID:9152014 PMID:11841787 PMID:12763371 PMID:16274885 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

affects response to substance

HMOX2 affects the susceptibility to Buthionine Sulfoximine

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heterogeneous nuclear ribonucleoprotein M

increases expression

Buthionine Sulfoximine results in increased expression of HNRNPM protein

NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762

G

heat shock protein 90 alpha family class A member 1

increases expression

Buthionine Sulfoximine results in increased expression of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

increases expression

Buthionine Sulfoximine results in increased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 4

increases expression

Buthionine Sulfoximine results in increased expression of HSPA4 protein

NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

increases expression

Buthionine Sulfoximine results in increased expression of HSPA8 mRNA

PMID:7626009 PMID:15707499

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

intercellular adhesion molecule 1

multiple interactions
increases expression

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]
[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of ICAM1 mRNA

PMID:11164475 PMID:20116392 PMID:20351055 PMID:29154782

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

insulin-like growth factor binding protein 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA]

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 10

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Buthionine Sulfoximine promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]

PMID:19339665 PMID:26177832

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]]

PMID:12688424 PMID:19339665

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 17A

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 alpha

multiple interactions

[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases secretion

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [hydroxyethyl methacrylate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of IL1B protein]

PMID:11970852 PMID:12433058 PMID:23986454 PMID:26149495 PMID:26177832 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 23 subunit alpha

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 4

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL4 protein; Buthionine Sulfoximine promotes the reaction [Methimazole results in increased expression of IL4 protein]

PMID:22407903 PMID:27421576

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases secretion
multiple interactions

Buthionine Sulfoximine results in increased secretion of IL6 protein
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL6 protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]

PMID:11970852 PMID:12433058 PMID:15601679 PMID:19339665 PMID:23986454 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

Janus kinase 1

increases expression

Buthionine Sulfoximine results in increased expression of JAK1 mRNA

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

decreases expression

Buthionine Sulfoximine results in decreased expression of JAK2 mRNA

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases activity

Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased activity of JUN protein]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA]
Buthionine Sulfoximine inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]
Buthionine Sulfoximine results in decreased activity of JUN protein

PMID:7626009 PMID:7743507 PMID:11341981 PMID:11841787 PMID:11849044 More...

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUNB mRNA]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

potassium voltage-gated channel subfamily A member 4

multiple interactions

[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein

NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162

G

potassium voltage-gated channel subfamily D member 2

multiple interactions

[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

Kelch-like ECH-associated protein 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KLF transcription factor 4

multiple interactions

Buthionine Sulfoximine inhibits the reaction [KLF4 results in decreased susceptibility to Cisplatin]

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 6

multiple interactions

Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

karyopherin subunit beta 1

increases expression

Buthionine Sulfoximine results in increased expression of KPNB1 protein

NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605

G

lipocalin 2

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of LCN2 mRNA
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA]
Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of LCN2 mRNA]

PMID:23939143 PMID:29154782 PMID:29679711 PMID:30853469

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lymphoid enhancer binding factor 1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of LEF1 protein

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

leucine-rich pentatricopeptide repeat containing

increases expression

Buthionine Sulfoximine results in increased expression of LRPPRC protein

NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of MAP1LC3B protein; Buthionine Sulfoximine results in increased expression of MAP1LC3B protein modified form
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein]; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in increased expression of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK1 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK1 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein]

PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 11

decreases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA
Sodium Selenite inhibits the reaction [Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA]

NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395

G

mitogen activated protein kinase 14

increases phosphorylation

Buthionine Sulfoximine results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK3 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK3 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein]

PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[antimony trioxide co-treated with Buthionine Sulfoximine] results in decreased expression of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [antimony trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK8 protein]

PMID:14701702 PMID:16112521 PMID:36343453

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

decreases phosphorylation

Buthionine Sulfoximine results in decreased phosphorylation of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

methionyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of MARS1 protein

NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495

G

myoglobin

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

myocyte enhancer factor 2a

increases expression

Buthionine Sulfoximine results in increased expression of MEF2A mRNA

NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948

G

O-6-methylguanine-DNA methyltransferase

multiple interactions
decreases activity

Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin]
Buthionine Sulfoximine results in decreased activity of MGMT protein

PMID:16039682 PMID:16950796

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microRNA 101-2

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA

NCBI chr 1:226,860,371...226,860,467
Ensembl chr 1:226,860,371...226,860,467

G

microRNA 106b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR106B mRNA

NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425

G

microRNA 127

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR127 mRNA

NCBI chr 6:128,546,215...128,546,311
Ensembl chr 6:128,546,215...128,546,311

G

microRNA 133b

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA

PMID:28263783 PMID:29679711 PMID:30853469

NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217

G

microRNA 136

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR136 mRNA

NCBI chr 6:128,549,096...128,549,177
Ensembl chr 6:128,549,096...128,549,177

G

microRNA 137

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR137 mRNA

NCBI chr 2:206,480,881...206,480,982
Ensembl chr 2:206,480,884...206,480,985

G

microRNA 138-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR138-1 mRNA

NCBI chr 8:122,300,966...122,301,064
Ensembl chr 8:122,300,966...122,301,064

G

microRNA 141

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR141 mRNA

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 148b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR148B mRNA

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 151

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR151 mRNA

NCBI chr 7:105,172,377...105,172,473

G

microRNA 184

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR184 mRNA

NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210

G

microRNA 187

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR187 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR187 mRNA

NCBI chr18:15,731,194...15,731,297
Ensembl chr18:15,731,194...15,731,297

G

microRNA 188

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR188 mRNA

NCBI chr X:15,247,715...15,247,794
Ensembl chr X:15,247,715...15,247,794

G

microRNA 190

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR190A mRNA

NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071

G

microRNA 19a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR19A mRNA

NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993

G

microRNA 200a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR200A mRNA

NCBI chr 5:166,648,494...166,648,582

G

microRNA 206

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA

PMID:28263783 PMID:29679711 PMID:30853469

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332

G

microRNA 20b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR20B mRNA

NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282

G

microRNA 210

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR210 mRNA

NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454

G

microRNA 211

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR211 mRNA

NCBI chr 1:117,777,539...117,777,644
Ensembl chr 1:117,777,539...117,777,644

G

microRNA 224

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR224 mRNA

NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169

G

microRNA 29b-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29B-1 mRNA

NCBI chr 4:59,650,987...59,651,067
Ensembl chr 4:59,650,986...59,651,067

G

microRNA 322

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR322 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR322 mRNA

NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688

G

microRNA 324

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR324 mRNA

NCBI chr10:54,734,680...54,734,762
Ensembl chr10:54,734,678...54,734,766

G

microRNA 328

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR328 mRNA

NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849

G

microRNA 337

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR337 mRNA

NCBI chr 6:128,538,903...128,538,999
Ensembl chr 6:128,538,902...128,538,998

G

microRNA 339

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR339 mRNA

NCBI chr12:15,277,546...15,277,641
Ensembl chr12:15,277,546...15,277,641

G

microRNA 34b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR34B mRNA

NCBI chr 8:51,410,244...51,410,327
Ensembl chr 8:51,410,244...51,410,327

G

microRNA 361

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR361 mRNA

NCBI chr X:78,246,206...78,246,275
Ensembl chr X:78,246,206...78,246,275

G

microRNA 375

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR375 mRNA

NCBI chr 9:76,457,911...76,457,985
Ensembl chr 9:76,457,911...76,457,985

G

microRNA 410

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR410 mRNA

NCBI chr 6:128,758,358...128,758,433
Ensembl chr 6:128,758,354...128,758,434

G

microRNA 449a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR449A mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR449A mRNA

NCBI chr 2:44,670,714...44,670,804
Ensembl chr 2:44,670,714...44,670,804

G

microRNA 450a-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR450A1 mRNA

NCBI chr X:132,801,380...132,801,470
Ensembl chr X:132,801,380...132,801,470

G

microRNA 455

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR455 mRNA

NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390

G

microRNA 671

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR671 mRNA

NCBI chr 4:10,580,747...10,580,827
Ensembl chr 4:10,580,738...10,580,835

G

microRNA 99a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR99A mRNA

NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523

G

matrix metallopeptidase 1

multiple interactions

[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

myeloperoxidase

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrial ribosomal protein S7

increases expression

Buthionine Sulfoximine results in increased expression of MRPS7 mRNA

NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129

G

metallothionein 1

increases expression
increases activity
multiple interactions

Buthionine Sulfoximine results in increased expression of MT1A mRNA
Buthionine Sulfoximine results in increased activity of MT1 promoter
Buthionine Sulfoximine promotes the reaction [Copper results in increased activity of MT1 promoter]; Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]; Dactinomycin inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]]
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MT1A mRNA]

PMID:7626009 PMID:8966720 PMID:9152014 PMID:14576086

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

multiple interactions

[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

metal-regulatory transcription factor 1

multiple interactions
decreases response to substance

MTF1 results in decreased susceptibility to [Buthionine Sulfoximine co-treated with cadmium sulfate]
MTF1 results in decreased susceptibility to Buthionine Sulfoximine

NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

asparaginyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of NARS1 protein

NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622

G

necdin, MAGE family member

increases expression

Buthionine Sulfoximine results in increased expression of NDN mRNA

NCBI chr 1:115,849,168...115,850,767
Ensembl chr 1:115,849,105...115,850,767

G

NADH:ubiquinone oxidoreductase subunit A13

increases expression

Buthionine Sulfoximine results in increased expression of NDUFA13 mRNA

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects expression
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [1,2-dihydroxynaphthalene analog results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein]
Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of and affects the localization of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased expression of and affects the localization of NFE2L2 protein]
Buthionine Sulfoximine affects the expression of NFE2L2 protein
Buthionine Sulfoximine results in increased expression of NFE2L2 mRNA
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of NFE2L2 mRNA; Buthionine Sulfoximine affects the localization of and results in increased activity of NFE2L2 protein; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Acrolein]; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [Dextromethorphan results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Acrolein]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide]]

PMID:17980396 PMID:18785192 PMID:19303893 PMID:19608619 PMID:20932822 More...

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]]

PMID:11970852 PMID:12433058

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
increases expression

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]

PMID:11970852 PMID:12433058 PMID:23472850

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

multiple interactions
affects response to substance
increases expression

Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of NGF mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]
NGF protein affects the susceptibility to Buthionine Sulfoximine

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NLR family, pyrin domain containing 3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of NLRP3 mRNA

PMID:23986454 PMID:26177832

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions
increases expression

[Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine]
Buthionine Sulfoximine results in increased expression of NOS2 mRNA
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]
Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased expression of NOS2 mRNA]

PMID:7532384 PMID:9826428 PMID:16259964 PMID:16933320 PMID:23939143

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC intracellular cholesterol transporter 1

decreases expression

Buthionine Sulfoximine results in decreased expression of NPC1 mRNA

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NAD(P)H quinone dehydrogenase 1

increases activity
increases expression
multiple interactions

Buthionine Sulfoximine results in increased activity of NQO1 protein
Buthionine Sulfoximine results in increased expression of NQO1 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of NQO1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]
[Buthionine Sulfoximine co-treated with chromium trioxide] results in increased activity of NQO1 protein; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased expression of NQO1 mRNA; [Tetrachlorodibenzodioxin co-treated with chromium trioxide co-treated with Buthionine Sulfoximine] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine inhibits the reaction [chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [[Benzene co-treated with Toluene] results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Benzene results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of NQO1 mRNA]
[Buthionine Sulfoximine co-treated with Endosulfan] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [Methylcholanthrene results in increased activity of NQO1 protein]; Methylcholanthrene promotes the reaction [Buthionine Sulfoximine results in increased activity of NQO1 protein]

PMID:16274885 PMID:16906435 PMID:18752316 PMID:20079720 PMID:21971136 More...

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 2, group F, member 2

increases expression

Buthionine Sulfoximine results in increased expression of NR2F2 mRNA

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

neurotrophic receptor tyrosine kinase 1

multiple interactions

Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]; Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

nuclear protein 1, transcriptional regulator

decreases expression

Buthionine Sulfoximine results in decreased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

ornithine decarboxylase 1

increases expression

Buthionine Sulfoximine results in increased expression of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

8-oxoguanine DNA glycosylase

multiple interactions
affects response to substance

Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA]
OGG1 protein affects the susceptibility to Buthionine Sulfoximine

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

orosomucoid 1

increases expression

Buthionine Sulfoximine results in increased expression of ORM1 mRNA; Buthionine Sulfoximine results in increased expression of ORM1 protein

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

prolyl 4-hydroxylase subunit alpha 1

decreases expression

Buthionine Sulfoximine results in decreased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly (ADP-ribose) polymerase 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of PARP1 protein]; Buthionine Sulfoximine promotes the reaction [wedelolactone results in increased cleavage of PARP1 protein]

PMID:20962031 PMID:22733624

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of PCK1 mRNA
SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA]

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

proliferating cell nuclear antigen

increases expression

Buthionine Sulfoximine results in increased expression of PCNA protein
Buthionine Sulfoximine results in increased expression of PCNA mRNA

PMID:9763232 PMID:15707499

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

platelet derived growth factor receptor beta

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB mRNA]]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB protein]]

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

protein disulfide isomerase family A, member 3

increases expression

Buthionine Sulfoximine results in increased expression of PDIA3 protein

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

pyruvate dehydrogenase kinase 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PDK1 protein]

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

phosphoribosylformylglycinamidine synthase

increases expression

Buthionine Sulfoximine results in increased expression of PFAS protein

NCBI chr10:53,690,301...53,711,811
Ensembl chr10:53,691,626...53,708,420

G

putative homeodomain transcription factor 1

increases expression

Buthionine Sulfoximine results in increased expression of PHTF1 mRNA

NCBI chr 2:191,470,849...191,537,399
Ensembl chr 2:191,473,130...191,512,078

G

plexin A3

decreases expression

Buthionine Sulfoximine results in decreased expression of PLXNA3 mRNA

NCBI chr X:152,115,699...152,131,608
Ensembl chr X:152,115,819...152,131,603

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; S-ethyl glutathione inhibits the reaction [Buthionine Sulfoximine results in increased expression of PPARG mRNA]
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG protein]

PMID:17602960 PMID:21520053 PMID:27358406

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase, Mg2+/Mn2+ dependent, 1G

decreases expression

Buthionine Sulfoximine results in decreased expression of PPM1G mRNA

NCBI chr 6:25,153,556...25,173,763
Ensembl chr 6:25,153,556...25,173,761

G

protein phosphatase 3 catalytic subunit alpha

increases expression

Buthionine Sulfoximine results in increased expression of PPP3CA mRNA

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

protein phosphatase 5, catalytic subunit

decreases expression

Buthionine Sulfoximine results in decreased expression of PPP5C mRNA

NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456

G

peroxiredoxin 1

increases expression
affects expression

Buthionine Sulfoximine results in increased expression of PRDX1 mRNA
Buthionine Sulfoximine affects the expression of PRDX1 mRNA

PMID:9506838 PMID:15707499

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

DNA primase subunit 2

decreases expression

Buthionine Sulfoximine results in decreased expression of PRIM2 mRNA

NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030

G

protein kinase C, alpha

decreases activity

Buthionine Sulfoximine results in decreased activity of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, beta

decreases activity

Buthionine Sulfoximine results in decreased activity of PRKCB protein

NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536

G

protein kinase C, delta

multiple interactions

Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PRKCD protein]
Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCD protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]

PMID:11118818 PMID:17171638

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, epsilon

multiple interactions

Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCE protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

pre-mRNA processing factor 19

increases expression

Buthionine Sulfoximine results in increased expression of PRPF19 protein

NCBI chr 1:207,541,582...207,552,664
Ensembl chr 1:207,541,595...207,552,662

G

phosphatase and tensin homolog

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2

increases expression

Buthionine Sulfoximine results in increased expression of PTK2 mRNA

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

protein tyrosine phosphatase, non-receptor type 1

increases oxidation

Buthionine Sulfoximine results in increased oxidation of PTPN1 protein

NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

Buthionine Sulfoximine results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

RB binding protein 6, ubiquitin ligase

decreases expression

Buthionine Sulfoximine results in decreased expression of RBBP6 mRNA

NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678

G

REL proto-oncogene, NF-kB subunit

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of REL protein]

PMID:11970852 PMID:12433058

NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression

[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [cinnamaldehyde results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of RELA protein]
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]]
Buthionine Sulfoximine affects the reaction [Dextromethorphan affects the activity of RELA protein]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased expression of RELA mRNA]
Buthionine Sulfoximine results in increased expression of RELA mRNA

PMID:11970852 PMID:12433058 PMID:18449455 PMID:20116392 PMID:20351055 More...

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELB protein]

PMID:11970852 PMID:12433058

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

RAR-related orphan receptor C

increases expression

Buthionine Sulfoximine results in increased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

ribosomal protein L10A

increases expression

Buthionine Sulfoximine results in increased expression of RPL10A mRNA

NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357

G

ribosomal protein L12

increases expression

Buthionine Sulfoximine results in increased expression of RPL12 mRNA

NCBI chr 3:16,264,269...16,266,645
Ensembl chr 3:16,264,251...16,266,642

G

ribosomal protein L3

decreases expression

Buthionine Sulfoximine results in decreased expression of RPL3 mRNA

NCBI chr 7:111,622,255...111,627,640
Ensembl chr 7:111,621,610...111,636,468

G

ribosomal protein L6

increases expression

Buthionine Sulfoximine results in increased expression of RPL6 mRNA

NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921

G

ribosomal protein L8

increases expression

Buthionine Sulfoximine results in increased expression of RPL8 mRNA

NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482
Ensembl chr 3:108,622,324...108,628,482

G

ribosomal protein lateral stalk subunit P0

increases expression

Buthionine Sulfoximine results in increased expression of RPLP0 mRNA

NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632

G

ribosomal protein lateral stalk subunit P1

increases expression

Buthionine Sulfoximine results in increased expression of RPLP1 mRNA

NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339

G

ribosomal protein S12

increases expression

Buthionine Sulfoximine results in increased expression of RPS12 mRNA

NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014

G

ribosomal protein S14

increases expression

Buthionine Sulfoximine results in increased expression of RPS14 mRNA

NCBI chr18:54,227,854...54,232,638
Ensembl chr18:54,227,854...54,233,166

G

ribosomal protein S15

increases expression

Buthionine Sulfoximine results in increased expression of RPS15 mRNA

NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450

G

ribosomal protein S20

increases expression

Buthionine Sulfoximine results in increased expression of RPS20 mRNA

NCBI chr 5:16,819,095...16,820,476
Ensembl chr 5:16,819,304...16,820,475
Ensembl chr 9:16,819,304...16,820,475
Ensembl chr 3:16,819,304...16,820,475

G

ribosomal protein S26

increases expression

Buthionine Sulfoximine results in increased expression of RPS26 mRNA

NCBI chr 7:1,057,332...1,058,882

G

ribosomal protein S6

increases expression

Buthionine Sulfoximine results in increased expression of RPS6 mRNA

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S7

increases expression

Buthionine Sulfoximine results in increased expression of RPS7 mRNA

NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145

G

ribosomal protein S8

increases expression

Buthionine Sulfoximine results in increased expression of RPS8 mRNA

NCBI chr 5:130,630,362...130,632,932
Ensembl chr 5:130,629,716...130,633,268

G

S100 calcium binding protein A8

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA]

PMID:23986454 PMID:26177832 PMID:28263783 PMID:30853469 PMID:31294483

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of S100A9 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA]

PMID:23986454 PMID:26177832 PMID:28263783 PMID:29154782 PMID:30853469 More...

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

small Cajal body-specific RNA 15

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1839 mRNA

NCBI chr 1:135,484,620...135,484,683
Ensembl chr 1:135,484,559...135,484,685
Ensembl chr 1:135,484,559...135,484,685

G

selectin E

multiple interactions

[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selenoprotein W

decreases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of SELENOW mRNA
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased expression of SELENOW mRNA

NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724
Ensembl chr 1:76,598,779...76,604,724

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

decreases expression

Buthionine Sulfoximine results in decreased expression of SERPINA3N mRNA

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

serpin family E member 1

increases expression

Buthionine Sulfoximine results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

increases expression

Buthionine Sulfoximine results in increased expression of SESN2 protein

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SH3 and multiple ankyrin repeat domains 3

decreases expression

Buthionine Sulfoximine results in decreased expression of SHANK3 mRNA

NCBI chr 7:120,568,707...120,630,796
Ensembl chr 7:120,570,402...120,630,374

G

siah E3 ubiquitin protein ligase 2

decreases expression

Buthionine Sulfoximine results in decreased expression of SIAH2 mRNA

NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950

G

solute carrier family 31 member 1

multiple interactions

[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [SLC31A1 protein results in increased import of Copper]; Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]; glutathione diethyl ester inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]]

NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228

G

synuclein alpha

increases expression

Buthionine Sulfoximine results in increased expression of SNCA protein

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

syntrophin, alpha 1

decreases expression

Buthionine Sulfoximine results in decreased expression of SNTA1 mRNA

NCBI chr 3:142,876,285...142,906,737
Ensembl chr 3:142,876,296...142,906,709

G

superoxide dismutase 1

increases expression

Buthionine Sulfoximine results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases response to substance

[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]
Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA]
SOD2 protein results in increased susceptibility to Buthionine Sulfoximine

PMID:8877099 PMID:10464329 PMID:15130278 PMID:32585298

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sorbitol dehydrogenase

multiple interactions

Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased secretion of SORD protein]

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

SRY-box transcription factor 4

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 protein

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

Sp1 transcription factor

increases activity
multiple interactions

Buthionine Sulfoximine results in increased activity of SP1 protein
mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

Sp3 transcription factor

multiple interactions
increases activity

mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP3 protein]

NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342

G

secreted phosphoprotein 1

decreases expression

Buthionine Sulfoximine results in decreased expression of SPP1 mRNA

PMID:15707499 PMID:15878706

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sterol regulatory element binding transcription factor 1

decreases expression

Buthionine Sulfoximine results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Metformin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein]]; Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein]

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

sulfiredoxin 1

increases expression

Buthionine Sulfoximine results in increased expression of SRXN1 protein

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

signal transducer and activator of transcription 3

increases activity
multiple interactions
increases expression

Buthionine Sulfoximine results in increased activity of STAT3 protein
[Troglitazone co-treated with Buthionine Sulfoximine] results in increased phosphorylation of STAT3 protein
Buthionine Sulfoximine results in increased expression of STAT3 mRNA

PMID:11841787 PMID:31294483

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

synapsin I

increases expression

Buthionine Sulfoximine results in increased expression of SYN1 mRNA

NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396

G

synaptophysin

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

tubulin folding cofactor A

increases expression

Buthionine Sulfoximine results in increased expression of TBCA mRNA

NCBI chr 2:26,011,714...26,065,909
Ensembl chr 2:26,011,795...26,065,907

G

T-box transcription factor 21

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

transforming growth factor alpha

multiple interactions

Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta receptor 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 protein]

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

transforming growth factor, beta receptor 2

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 protein]

NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228

G

thyroid hormone responsive

decreases expression

Buthionine Sulfoximine results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

TERF1 interacting nuclear factor 2

increases expression

Buthionine Sulfoximine results in increased expression of TINF2 mRNA

NCBI chr15:29,170,663...29,178,015
Ensembl chr15:29,170,652...29,176,984

G

TLE family member 5, transcriptional modulator

increases expression

Buthionine Sulfoximine results in increased expression of TLE5 mRNA

NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113

G

toll-like receptor 2

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein]

PMID:23986454 PMID:26177832

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

toll-like receptor 9

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

thymosin, beta 10

increases expression

Buthionine Sulfoximine results in increased expression of TMSB10 mRNA

NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028

G

tumor necrosis factor

multiple interactions
increases secretion

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein]; [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of TNF mRNA; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TNF mRNA; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine]

PMID:7532384 PMID:11167962 PMID:11970852 PMID:12433058 PMID:15601679 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase II beta

decreases expression

Buthionine Sulfoximine results in decreased expression of TOP2B mRNA

NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085

G

tumor protein p53

multiple interactions
increases expression

[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein]
[cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein
Buthionine Sulfoximine results in increased expression of TRP53 protein

PMID:12807757 PMID:18552690 PMID:25410294

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

increases expression

Buthionine Sulfoximine results in increased expression of TPI1 protein

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

TNF receptor-associated protein 1

increases expression

Buthionine Sulfoximine results in increased expression of TRAP1 protein

NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981

G

transient receptor potential cation channel, subfamily M, member 2

multiple interactions

4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]

NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine; [Ruthenium Red results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

thioredoxin 1

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of TXN1 mRNA
Buthionine Sulfoximine inhibits the reaction [arsenite results in increased expression of TXN protein]
NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]

PMID:23472850 PMID:36343453

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

multiple interactions
increases response to substance
increases expression

Buthionine Sulfoximine inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased activity of TXNRD1 protein]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased activity of TXNRD1 protein]
TXNRD1 gene mutant form results in increased susceptibility to Buthionine Sulfoximine
Buthionine Sulfoximine results in increased expression of TXNRD1 mRNA
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of TXNRD1 protein

PMID:12663510 PMID:16288907 PMID:19010381 PMID:24853413 PMID:36343453

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

U2 small nuclear RNA auxiliary factor 2

increases expression

Buthionine Sulfoximine results in increased expression of U2AF2 protein

NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492

G

ubiquitin C

increases expression

Buthionine Sulfoximine results in increased expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

vascular cell adhesion molecule 1

multiple interactions

[[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]
[Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of VCAM1 mRNA

PMID:16271621 PMID:21971136 PMID:31294483

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions

Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

VPS26 endosomal protein sorting factor C

decreases expression

Buthionine Sulfoximine results in decreased expression of VPS26C mRNA

NCBI chr11:33,813,467...33,841,883
Ensembl chr11:33,792,389...33,841,447

G

xin actin-binding repeat containing 1

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA

NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349

G

zinc finger protein 422

decreases expression

Buthionine Sulfoximine results in decreased expression of ZFP422 mRNA

NCBI chr 4:149,885,805...149,893,287
Ensembl chr 4:149,885,600...149,893,257

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19844
role	19820
application	19663
NMR chemical shift reference compound	18004
ammonia	17797
organic amino compound	17822
amino acid	15956
alpha-amino acid	13872
non-proteinogenic alpha-amino acid	3795
homocysteines	418
2-amino-4-(S-butylsulfonimidoyl)butanoic acid +	325
S-(5-deoxy-D-ribos-5-yl)-L-homocysteine +	0
S-adenosyl-L-homocysteine	28
S-inosyl-L-homocysteine	0
cystathionines +	6
homocysteine +	137
Path 2
Term	Annotations
CHEBI ontology	19844
subatomic particle	19842
composite particle	19842
hadron	19842
baryon	19842
nucleon	19809
atomic nucleus	19842
atom	19842
main group element atom	19792
main group molecular entity	19792
s-block molecular entity	19626
hydrogen molecular entity	19613
hydrides	19115
inorganic hydride	18121
pnictogen hydride	18110
nitrogen hydride	18017
azane	17823
ammonia	17797
organic amino compound	17822
amino acid	15956
non-proteinogenic amino acid	3988
non-proteinogenic alpha-amino acid	3795
homocysteines	418
2-amino-4-(S-butylsulfonimidoyl)butanoic acid +	325
S-(5-deoxy-D-ribos-5-yl)-L-homocysteine +	0
S-adenosyl-L-homocysteine	28
S-inosyl-L-homocysteine	0
cystathionines +	6
homocysteine +	137

paths to the root